BRL-302

N/A

Report date: 2025/04/15 16:03:34

Base Information

Drug NameBRL-302
Drug Alias NameUniversal BCMA-CD19 CART cell therapyPSMA-UCAR TBRL-302
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-cell maturation protein modulatorsB-lymphocyte antigen CD19 modulators
TargetsB-cell maturation proteinB-lymphocyte antigen CD19
Therapy Area/IndicationsSolid tumoursAutoimmune DiseasesLupus Nephritis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBRL Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesBRL Medicine Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursAutoimmune DiseasesLupus Nephritis +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A